Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Dec 14, 2013; 19(46): 8474-8488
Published online Dec 14, 2013. doi: 10.3748/wjg.v19.i46.8474
Published online Dec 14, 2013. doi: 10.3748/wjg.v19.i46.8474
Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients
Giuseppe Aprile, Stefania Eufemia Lutrino, Laura Ferrari, Mariaelena Casagrande, Marta Bonotto, Elena Ongaro, Fabio Puglisi, Department of Oncology, University and General Hospital, 33100 Udine, Italy
Fabio Puglisi, Department of Medical and Biological Sciences, University of Udine, 33100 Udine, Italy
Author contributions: All authors contributed equally to the intellectual conception of the manuscript and approved the final version; Aprile G, Lutrino ES, Ferrari L, Casagrande M, Bonotto M and Ongaro E performed extensive literature research and drafted the article; Aprile G and Puglisi F revised the manuscript critically.
Correspondence to: Giuseppe Aprile, MD, Department of Oncology, University and General Hospital, Piazzale S Maria della Misericordia 1, 33100 Udine, Italy. aprile.giuseppe@aoud.sanita.fvg.it
Telephone: +39-432-559308 Fax: +39-432-559305
Received: September 18, 2013
Revised: November 13, 2013
Accepted: December 3, 2013
Published online: December 14, 2013
Revised: November 13, 2013
Accepted: December 3, 2013
Published online: December 14, 2013
Core Tip
Core tip: The choice of the first-line therapy is crucial for patients with advanced, unresectable colorectal cancer. The aim of this review is to critically focus on updated scientific data that medical oncologists need to interpret to make the most appropriate evidence-based choice among many possible treatment options.